Looking at the universe of stocks we cover at Dividend Channel, on 12/17/13, Helios Advantage Income Fund (HAV) will trade ex-dividend, for its monthly dividend of $0.0725, payable on 12/27/13. As a percentage of HAV's recent stock price of $8.95, this dividend works out to approximately 0.81%, so look for shares of Helios Advantage Income Fund to trade 0.81% lower — all else being equal — when HAV shares open for trading on 12/17/13.Below is a dividend history chart for HAV, showing historical dividends prior to the most recent $0.0725 declared by Helios Advantage Income Fund: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from HAV is likely to continue, and whether the current estimated yield of 9.72% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of HAV shares, versus its 200 day moving average: Looking at the chart above, HAV's low point in its 52 week range is $7.87 per share, with $9.34 as the 52 week high point — that compares with a last trade of $8.95. In Friday trading, Helios Advantage Income Fund shares are currently up about 0.2% on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
Chipotle Initiated Outperform at Credit Suisse With $870 Price Target
Credit Suisse initiated coverage of Chipotle Mexican Grill with an outperform recommendation and price target of $870. The stock gained more than $10.
AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
The Most Important Thing to Watch in Micron's Earnings Report
What's the most important thing investors should listen to during Micron earnings call Tuesday? Action Alerts PLUS senior analyst Jeff Marks has the answer.